The role of PI3 kinase inhibition in various settings in metastatic breast cancer and a payer perspective on differentiating breast cancer at various stages of disease progression.
Testing patients who have received CDK4/6 inhibitors in metastatic breast cancer (MBC) as well as testing patients with ctDNA upon disease progression with a single gene test versus NGS.
February 8th 2021, 5:00pm
A targeted cue-to-action campaign of outreach, education, and incentive can improve uptake of screening mammography.
January 19th 2021, 10:24pm
Severe mental illnesses that precede a breast cancer diagnosis may increase the risk of both all-cause and cancer-specific mortality among women with Medicaid coverage.
January 13th 2021, 2:00pm
Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera, said that attention on finding biomarkers for metastatic reoccurrence needs to be directed at women with a high risk of this happening.
January 11th 2021, 9:20pm
A more aggressive tumor microenvironment may be to blame for the exaggerated inflammatory response more often seen in Black women with breast cancer compared with White women.
January 9th 2021, 2:00pm
Changes in circulating tumor DNA (ctDNA) are indicative of treatment response in early-stage breast cancer, pointed out Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
January 4th 2021, 9:02pm
An abstract from last month’s San Antonio Breast Cancer Symposium identifies factors linked with longer-term controlled substance use after treatment of breast cancer with mastectomy plus breast reconstruction in women receiving opioids, benzodiazepines, and other sedative/hypnotics.
January 1st 2021, 2:00pm
Through neoadjuvant chemotherapy we can downstage tumors, assess drug efficacy, and better segregate women by prognosis status for adjuvant treatment, explained Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
December 23rd 2020, 10:01pm
We examine the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.
December 23rd 2020, 9:30pm
Supplemental materials for article examining the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.
December 23rd 2020, 7:00pm
This article describes treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.
.jpg?w=200&fit=crop&auto=format)
